Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 59.3141
- Book/Share 20.4356
- PB 39.4497
- Debt/Equity 2.1838
- CurrentRatio 1.2777
- ROIC 0.277
- MktCap 722030480052.0
- FreeCF/Share -0.0559
- PFCF -14383.0773
- PE 52.2367
- Debt/Assets 0.3954
- DivYield 0.0072
- ROE 0.8836
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
News
Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performance
Published: October 20, 2025 by: Proactive Investors
Sentiment: Neutral
Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affecting margins and growth.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Read More
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Published: October 17, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Read More
Is Trump Going to Kill the GLP-1 Cash Cow?
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Negative
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.
Read More
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Published: October 17, 2025 by: Benzinga
Sentiment: Negative
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).
Read More
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices
Published: October 17, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY), two major pharmaceutical companies that produce weight-loss drugs, dropped sharply following comments from US president Donald Trump about reductions in the prices of these medicines. During a White House event focused on fertility treatments and drug pricing, Trump suggested that the cost of drugs like Novo Nordisk's Ozempic (semaglutide), used for diabetes and weight management, would soon be “much lower.
Read More
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.
Read More
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Read More
Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company reported strong Phase 3 results for its oral GLP-1 drug orforglipron in type 2 diabetes, meeting all primary and secondary endpoints. LLY's GLP-1 franchise, including Mounjaro, Zepbound, and orforglipron, underpins its $800bn valuation and continued bullish long-term growth outlook. Despite high valuation and industry headwinds, LLY's management, product pipeline, and market dominance support a 20% upside potential over 18-24 months.
Read More
How LLY Stock Delivered $47 Billion To Shareholders
Published: October 15, 2025 by: Forbes
Sentiment: Positive
In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the stock posting 9% year-to-date returns, despite experiencing some volatility from its peak of $937 earlier in the year, while demonstrating remarkable resilience in the face of increased competition in the diabetes and obesity treatment markets.
Read More
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)
Published: October 13, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of decline. LLY's robust pipeline, expansion into cardiometabolic and oncology adjacencies, and manufacturing readiness support its competitive edge over NVO. Despite near-term gross margin pressures, LLY's valuation is de-risked, and its growth strategy could bolster near-term catalysts from its diversified pipeline.
Read More
Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
Published: October 13, 2025 by: Reuters
Sentiment: Positive
Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.
Read More
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
Read More
A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy?
Published: October 09, 2025 by: Forbes
Sentiment: Positive
Eli Lilly (LLY) stock merits your attention. Why? Because it offers monopoly-like high margins at a reduced price.
Read More
Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports
Published: October 07, 2025 by: Reuters
Sentiment: Positive
Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly , STAT News reported on Tuesday.
Read More
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
Read More
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
Published: October 06, 2025 by: MarketBeat
Sentiment: Neutral
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Published: October 06, 2025 by: Schwab Network
Sentiment: Neutral
Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded access to GLP-1s as indicators these companies will see wider moats for their products.
Read More
Top 50 High-Quality Dividend Growth Stocks For October 2025
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future return estimates of at least 10%, with 15 appearing potentially undervalued by my Free Cash Flow model. Top-ranked stocks include MKTX, RMD, MPWR, RACE, and MSCI, each offering strong projected returns driven by yield, valuation upside, and EPS growth.
Read More
Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)-- #AI--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly's global network of experts.
Read More
Buy LLY Stock At $820?
Published: October 03, 2025 by: Forbes
Sentiment: Positive
The entire pharmaceutical sector is experiencing a rerating this week, as investors realize the adverse impact of tariffs and drug price cuts won't be as severe as previously anticipated. While most major pharma stocks have rallied, Eli Lilly stock (NYSE: LLY) warrants particular attention.
Read More
How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Building a resilient retirement portfolio requires a mix of disruption-proof income from REITs, midstream energy, and high-yielding assets, plus growth stocks and ETFs. Current market challenges—AI disruption, weak job market, inflation risks—make long-term planning difficult, but also highlight the need for self-reliance and diversification. Core portfolio holdings should include large, proven REITs, natural gas midstream companies, select high-yield stocks, BDCs, preferred equity ETFs, and actively managed income funds.
Read More
Why Eli Lilly Is The Lion's Share Of My Portfolio
Published: October 02, 2025 by: Seeking Alpha
Sentiment: Positive
Healthcare is underowned; 2026 rate cuts and policy clarity should trigger inflows. As XLV's largest weight and obesity leader, Lilly will capture outsized demand during the sector re-rating cycle. Orforglipron, first true oral GLP-1, solves compliance issues and expands TAM. LLY's $1B pre-launch inventory and $15B+ capex signal FDA approval certainty and industrialized pill-based obesity treatment scale. Diversified growth via Alzheimer's, immunology, and oncology pipelines, backed by disciplined governance and supply-first execution. Supports long-term compounding and >40% 12-month upside from $830, with re-rating potential toward ~35× P/E.
Read More
Another Surging Pharma Stock to Watch Right Now
Published: October 01, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical concern Eli Lilly And Co (NYSE:LLY ) is charging 7.2% higher to trade at $821.20 this afternoon.
Read More
Top Stock Movers Now: Nike, Eli Lilly, Corteva, AES, and More
Published: October 01, 2025 by: Investopedia
Sentiment: Negative
The S&P 500, Dow, and Nasdaq were little changed Wednesday afternoon, as a federal government shutdown took effect.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000